Theriva Biologics Management
Management criteria checks 2/4
Theriva Biologics' CEO is Steve Shallcross, appointed in Jun 2015, has a tenure of 8.83 years. total yearly compensation is $1.27M, comprised of 48.3% salary and 51.7% bonuses, including company stock and options. directly owns 1.46% of the company’s shares, worth $107.70K. The average tenure of the management team and the board of directors is 8.8 years and 7.6 years respectively.
Key information
Steve Shallcross
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 48.3% |
| CEO tenure | 8.8yrs |
| CEO ownership | 1.5% |
| Management average tenure | 8.8yrs |
| Board average tenure | 7.6yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$1m | US$614k | -US$18m |
| Sep 30 2023 | n/a | n/a | -US$19m |
| Jun 30 2023 | n/a | n/a | -US$21m |
| Mar 31 2023 | n/a | n/a | -US$20m |
| Dec 31 2022 | US$1m | US$585k | -US$20m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$17m |
| Mar 31 2022 | n/a | n/a | -US$16m |
| Dec 31 2021 | US$1m | US$585k | -US$23m |
| Sep 30 2021 | n/a | n/a | -US$21m |
| Jun 30 2021 | n/a | n/a | -US$20m |
| Mar 31 2021 | n/a | n/a | -US$21m |
| Dec 31 2020 | US$1m | US$565k | -US$13m |
| Sep 30 2020 | n/a | n/a | -US$13m |
| Jun 30 2020 | n/a | n/a | -US$15m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$1m | US$550k | -US$16m |
| Sep 30 2019 | n/a | n/a | -US$28m |
| Jun 30 2019 | n/a | n/a | -US$26m |
| Mar 31 2019 | n/a | n/a | -US$27m |
| Dec 31 2018 | US$963k | US$489k | -US$25m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$22m |
| Mar 31 2018 | n/a | n/a | -US$22m |
| Dec 31 2017 | US$799k | US$347k | -US$22m |
Compensation vs Market: Steve's total compensation ($USD1.27M) is above average for companies of similar size in the US market ($USD674.64K).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
CEO
Steve Shallcross (62 yo)
8.8yrs
Tenure
US$1,271,913
Compensation
Mr. Steven A. Shallcross, also known as Steve, CPA, was an Independent Director of Forza X1, Inc. since December 2021. He served as Independent Director at Twin Vee Powercats Co. since April 8, 2021 until...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO | 8.8yrs | US$1.27m | 1.46% $ 107.7k | |
| Head of Product & Corporate Development | no data | no data | no data | |
| Senior Vice President of Research & Development | 11.5yrs | no data | no data | |
| Senior VP of Discovery & Chairman of Scientific Advisory Board | less than a year | no data | no data | |
| Senior Director of Project Operations | no data | no data | no data |
8.8yrs
Average Tenure
Experienced Management: TOVX's management team is seasoned and experienced (8.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO | 5.3yrs | US$1.27m | 1.46% $ 107.7k | |
| Senior VP of Discovery & Chairman of Scientific Advisory Board | 1.9yrs | no data | no data | |
| Independent Director | 3.4yrs | US$110.51k | no data | |
| Independent Non-Executive Chairman | 18.3yrs | US$216.88k | 0.0038% $ 281.5 | |
| Member of Scientific Advisory Board | 1.9yrs | no data | no data | |
| Independent Director | 18.3yrs | US$114.38k | no data | |
| Member of C Difficile Clinical Advisory Board | 9.8yrs | no data | no data | |
| Member of C Difficile Clinical Advisory Board | 9.8yrs | no data | no data | |
| Member of C Difficile Clinical Advisory Board | 9.8yrs | no data | no data | |
| Chairman of C Difficile Clinical Advisory Board | 9.8yrs | no data | no data | |
| Member of Intestinal Alkaline Phosphatase Clinical Advisory Board | 3.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.9yrs | no data | no data |
7.6yrs
Average Tenure
62yo
Average Age
Experienced Board: TOVX's board of directors are considered experienced (7.6 years average tenure).